Product
Milademetan
Aliases
DS-3032b
5 clinical trials
1 drug
1 abstract
15 indications
Indication
Advanced Solid TumorIndication
CDKN2AIndication
NSCLCIndication
Bladder Urothelial CarcinomaIndication
MelanomaIndication
Pancreatic AdenocarcinomaIndication
HNSCCIndication
Renal Cell CarcinomaIndication
MesotheliomaIndication
Stomach CancerIndication
Cardiac RepolarizationIndication
Acute Myeloid LeukemiaIndication
Breast CancerIndication
Recurrent Acute Myeloid LeukemiaDrug
MilademetanIndication
LymphomaClinical trial
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)Status: Withdrawn, Estimated PCD: 2023-05-30
Clinical trial
A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy SubjectsStatus: Terminated, Estimated PCD: 2023-06-08
Clinical trial
Phase 1, Open-label, Dose Escalation Study of Milademetan, an Oral MDM2 Inhibitor, to Assess Safety, Tolerability and Pharmacokinetics in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2019-09-11
Clinical trial
Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II TrialStatus: Terminated, Estimated PCD: 2023-11-24
Clinical trial
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)Status: Terminated, Estimated PCD: 2022-04-03